BMC genomics

[1] Performance of rotation forest ensemble classifier and feature extractor in predicting protein interactions using amino acid sequences.

[2] antiviral functions of human immunodeficiency virus type 1 (hiv-1)-specific igg antibodies: effects of antiretroviral therapy and implications for therapeutic hiv-1 vaccine design

[3] retroviruses as myeloid cell riders: what natural human siglec-1 “knockouts” tell us about pathogenesis

[4] antiretroviral resistance in individuals presenting therapeutic failure and subtypes of the human immunodeficiency virus type 1 in the northeast region of brazil

[5] Zinc Status in Human Immunodeficiency Virus Type 1 Infection and Illicit Drug Use

[6] Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression

[7] Plasmodium Falciparum malaria and perinatally acquired human immunodeficiency virus type 1 infection in Kinshasa, Zaire. A prospective, longitudinal cohort study of 587 children

[8] Immune responses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre- and post-highly active antiretroviral therapy and re-vaccination

[9] Virucidal effect of stimulated eosinophils on human immunodeficiency virus type 1

[10] Immune responses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre- and post-highly active antiretroviral therapy and revaccination

[11] neutralizing antibodies in brazilian sera against three strains of human immunodeficiency virus type 1 (hiv-1)

[12] development of a live recombinant bcg expressing human immunodeficiency virus type 1 (hiv-1) gag using a pmyong2 vector system: potential use as a novel hiv-1 vaccine

[13] antiviral functions of human immunodeficiency virus type 1 (hiv-1)-specific igg antibodies: effects of antiretroviral therapy and implications for therapeutic hiv-1 vaccine design

[14] antiretroviral resistance mutations in human immunodeficiency virus type 1 infected patients enrolled in genotype testing at the central public health laboratory, são paulo, brazil: preliminary results

[15] antiretroviral resistance in individuals presenting therapeutic failure and subtypes of the human immunodeficiency virus type 1 in the northeast region of brazil

[16] Survival in children with perinatally acquired human immunodeficiency virus type 1 infection

[17] Timing of perinatal human immunodeficiency virus type 1 infection and rate of neurodevelopment. The Women and Infant Transmission Study Group

[18] Micronutrients and Human Immunodeficiency Virus Type 1 Disease Progression among Adults and Children

[19] Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies